TC-Evo · Molecular and functional evolution of human CD8+ T cell repertoires
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2018-05-01 → 2021-07-13
- Финансиране от ЕС
- 249 179 €
- Участници
- 2
- Схема
- MSCA-IF-GF
Линиите свързват координатора с партньорите.
Накратко на български
CD8+ Т-клетките, които разпознават и унищожават заразени от вируси клетки, се проучват в различните етапи от живота на човека. Това помага да се разбере как имунната памет се развива, поддържа и изгубва от раждането до старостта.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Molecular and functional evolution of human CD8+ T cell repertoires
During our life-time, we encounter many pathogens (infectious agents like viruses). The immune system is our main defence mechanism to prevent us from getting sick. One of the key players is adaptive immunity (including T cells), which gets its name from is ability to change and adapt depending on the pathogen you encounter. T cells detect and clear these pathogens in a highly specific manner. In other words, when you get infected with an influenza virus your adaptive immune system comes into action, but only activates those immune cells that are able to recognise this particular influenza virus strain. The initial response upon the first encounter with a pathogen is relatively slow. An important feature of the adaptive immune system is that it remembers the pathogen you encountered. This immunological memory enables your immune system to respond faster and stronger when you get re-infected with the same pathogen. This way your immune system prevents you from getting sick a second time. It is not fully understood how our immune response develops (children), maintains (adults) and loses (elderly) memory and strong functionality over the years. TC-Evo’s overarching aim: To gain fundamental knowledge on how our immune system develops during immunologically-distinct phases of our life, from birth to old age. Tc-Evo focuses on a specific part of the adaptive immune system, the so called CD8 T cells, also known as killer cells. Killer T cells have special receptors on their cell surface, the T cell receptors (TCRs), which enables them to recognise virus infected cells in a highly specific manner. Once they recognise an infected cell, they can kill this cell before it makes new viruses that could infect other cells (Figure 1). Previous research on killer T cells mainly focused on their function in adults (adults are known to have excellent and very specific killer T cells), and some studies were done in elderly. However, research that focuses on how these killer T cells develop during childhood are non-existent. Studying the killer T cell response in children is of special interest as children cope exceptionally well with novel virus infections. Not only are children able to form a strong memory response, their ability to recover from novel virus infections is superior to that of other age groups (Figure 2). The first part of the Tc-Evo project took place at the University of Melbourne in Australia and focused on answering the overarching aim of this project using the most recent and ground-breaking technology to study killer T cell responses in the greatest detail as possible. The second part of the Tc-Evo project took place at Sanquin in the Netherlands. The aim of this second part was to implement this new ground-breaking technology at a European research institute, while focusing on a slightly different cell type. Due to COVID-19, this part was revised to study COVID-19 specific immunity after infection and vaccination in high-risk groups including autoimmune patients. Importance: Fundamental knowledge on how or immune system develops while ageing is especially relevant given our ageing population and is likely to contribute to new therapies against a wide variety of diseases. Furthermore, the Tc-Evo research project is likely to give new insights on how to develop new vaccines strategies that train our immune system to develop stronger localised immune memory response while retaining some flexibility in order to cope with new/slightly different pathogenic infections. For example, a single vaccine that gives long-lasting protection against seasonal and pandemic viruses.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Humans are equipped with a sophisticated immune system, especially adaptive immunity, which is characterized by the finest antigen specificity. The evolution of such fine antigen specificity across human lifespan is far from being known, although it is observe that the strength of the adaptive immune response varies throughout human lifetime. Published data suggest that T cells receptors (TCRs) continuously change their characteristics. I aim to provide fundamental knowledge on the evolution of T cell repertoires during immunologically-distinct phases of human lifetime by dissecting the evolution of the influenza virus-specific T cell repertoire in children, adults and elderly at the greatest level of resolution and technological innovation and link this to their TCR characteristics. At the Peter Doherty Institute, Melbourne, Australia, I will use state-of-the-art comprehensive immunological analyses to identify molecular switches, which I will use to establish an immunological model to predict the strength of the CD8+ T cell response. I will bring this cutting-edge multi-disciplinary platform to Europe (Sanquin, Amsterdam, The Netherlands) where I will use this platform to study the underlining mechanisms that drive tissue residency of T cells. I will gain knowledge and skills on studying TCRs, tissue resident T cells, bioinformatics and structural biology, while working in close collaboration with world-renowned experts in the field, namely Profs. Kedzierska, van Lier, Luciani, Gras, Beyer and Schulze. These state-of-the-art comprehensive immunological analyses will inevitably yield important insights into protective vs detrimental human immune responses, which will aid early interventions, treatment and help understand and overcome technical challenges of developing broadly-protective vaccines. The MSCA will strengthen my position as an independent researcher and will greatly increase my chances for a tenure-track/fixed position at an European research institute.
Оригинален текст от CORDIS (на английски).
Участници
- Stichting Sanquin Bloedvoorziening · AmsterdamКоординаторНидерландия
- UNIVERSITY OF MELBOURNE · MelbourneАвстралия
Връзки
- Виж в CORDIS
- DOI: 10.3030/792532
- https://www.sanquin.org/research/who-is-who/employee/name/carolien-van-de-sandt
Данни: CORDIS, © Европейски съюз
